Pancreatic Cancer Research

ResearcherShenzhen UniversityActive in the last 2 years

Guocheng Zhong

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5101108854. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 5

  1. SLP-76/LAT AND-gated CAR-T cells mediate highly specific and durable antitumor activity in pancreatic ductal adenocarcinoma with reduced gastric toxicity Co-author DOI 10.21203/rs.3.rs-9121312/v1↗
  2. The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy. Co-author DOI 10.1016/j.ymthe.2025.01.012↗
  3. CLDN18.2-targeting STAR-T cell therapy for pancreatic cancer: a strategy to minimize gastric off-tumor toxicity compared to CLDN18.2 CAR-T. Co-author DOI 10.1038/s41388-025-03414-z↗
  4. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report. Co-author DOI 10.3389/fimmu.2024.1325860↗
  5. [Efficacy evaluation of high intensity focused ultrasound combined with intra-arterial infusion of gemcitabine in the treatment of pancreatic cancer]. Co-author PMID 22490861↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li Yu · 1 shared paper, 2026 · strength 0.26
  2. Teeranut Asavasupreechar · 1 shared paper, 2026 · strength 0.26
  3. Li Yu · 1 shared paper, 2025 · strength 0.26
  4. Wei Zhang · 1 shared paper, 2025 · strength 0.26
  5. Li J. Yu · 1 shared paper, 2025 · strength 0.21
  6. Li Yu · 1 shared paper, 2024 · strength 0.20
  7. Bo Zhu · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.